ArticleBMC cardiovascular disorders2025
Effects of SGLT2 inhibitors on cognitive impairment in elderly inpatients with heart failure with reduced ejection fraction: a prospective cohort study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHeart failure with reduced ejection fraction (HFrEF) and cognitive impairment are significant challenges faced by global healthcare systems. Clinical studies on the impact of drugs for HFrEF on cognitive impairment are very limited. We aimed to assess the effects of regular use of Sodium-Glucose cotransporter 2 inhibitor (SGLT2i) on cognitive impairment in elderly inpatients with HFrEF.
methodsA single center prospective cohort was conducted from October 2022 to October 2023. Inpatients ≥ 65 years old with HFrEF were evaluated. Cognitive function was assessed by the Chinese version of the Mini-Mental State Examination (MMSE), and patients with MMSE score < 27 were included in the study and followed up for 6 months. We divided the population into the groups of regular SGLT2i users (R-SGLT2i) and Non-regular SGLT2i users (Non-R-SGLT2i). A multivariate logistic regression model was used to determine the relationship between regular use of SGLT2i and MMSE score.
resultsA total of 113 elderly hospitalized HFrEF patients with cognitive impairment were completed the study, and 54 (47.8%) patients were in R-SGLT2i, and 67.9% were male. The baseline MMSE score for the Non-R-SGLT2i and R-SGLT2i were 20.03 ± 1.50 and 20.19 ± 1.92 (P = 0.640). After 6 months of follow-up and reevaluation, the MMSE score of the Non-R-SGLT2i and R-SGLT2i were 19.78 ± 1.99 and 22.28 ± 1.76 (P < 0.001). After adjusting for age, education, left ventricular ejection fraction and type 2 diabetes, the regular use of SGLT2i was associated with higher MMSE score [OR = 3.22, 95% CI (1.37–7.55), P = 0.007].
conclusionsThis study shows that regular use of SGLT2i have an improving effect on cognitive impairment in elderly HFrEF patients.
trial registrationChiCTR2200066070; date of registration: 11/23/2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.